Literature DB >> 11036063

Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.

H W Murray1.   

Abstract

T-cell-deficient nude mice infected with Leishmania donovani were treated with miltefosine and then given either no treatment or intermittent miltefosine. Intracellular visceral infection recurred in untreated mice but was suppressed by once- or twice-weekly oral administration of miltefosine. Miltefosine may be useful as oral maintenance therapy for T-cell-deficient patients with visceral leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11036063      PMCID: PMC101643          DOI: 10.1128/AAC.44.11.3235-3236.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.

Authors:  H W Murray
Journal:  Int J Infect Dis       Date:  2000       Impact factor: 3.623

2.  Oral treatment of visceral leishmaniasis with miltefosine.

Authors:  S Sundar; L B Gupta; M K Makharia; M K Singh; A Voss; F Rosenkaimer; J Engel; H W Murray
Journal:  Ann Trop Med Parasitol       Date:  1999-09

Review 3.  Kala-azar as an AIDS-related opportunistic infection.

Authors:  H W Murray
Journal:  AIDS Patient Care STDS       Date:  1999-08       Impact factor: 5.078

4.  Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.

Authors:  F Laguna; R López-Vélez; F Pulido; A Salas; J Torre-Cisneros; E Torres; F J Medrano; J Sanz; G Picó; J Gómez-Rodrigo; J Pasquau; J Alvar
Journal:  AIDS       Date:  1999-06-18       Impact factor: 4.177

5.  Antithymocyte serum suppression of immunity in mice immunized to Leishmania donovani.

Authors:  G L Runey; J C Jarecki-Black; M W Runey; A B Glassman
Journal:  Ann Clin Lab Sci       Date:  1990 Jul-Aug       Impact factor: 1.256

6.  Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.

Authors:  T K Jha; S Sundar; C P Thakur; P Bachmann; J Karbwang; C Fischer; A Voss; J Berman
Journal:  N Engl J Med       Date:  1999-12-09       Impact factor: 91.245

7.  Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms.

Authors:  H W Murray; S Delph-Etienne
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

8.  Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients.

Authors:  E Ribera; I Ocaña; J de Otero; E Cortes; I Gasser; A Pahissa
Journal:  Am J Med       Date:  1996-05       Impact factor: 4.965

9.  Models of relapse of experimental visceral leishmaniasis.

Authors:  H W Murray; J Hariprashad; R E Fichtl
Journal:  J Infect Dis       Date:  1996-04       Impact factor: 5.226

10.  Is leishmaniasis ever cured?

Authors:  R A de Rossell; R J de Duran; O Rossell; A M Rodríguez
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 May-Jun       Impact factor: 2.184

View more
  8 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.

Authors:  Victor B Saraiva; Daniel Gibaldi; José O Previato; Lucia Mendonça-Previato; Marcelo T Bozza; Célio G Freire-De-Lima; Norton Heise
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.

Authors:  Nishi Shakya; Preeti Bajpai; Suman Gupta
Journal:  J Parasit Dis       Date:  2011-05-20

4.  Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.

Authors:  M Rakotomanga; S Blanc; K Gaudin; P Chaminade; P M Loiseau
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

5.  Miltefosine (Impavido): the first oral treatment against leishmaniasis.

Authors:  H Sindermann; S L Croft; K R Engel; W Bommer; H J Eibl; C Unger; J Engel
Journal:  Med Microbiol Immunol       Date:  2003-09-26       Impact factor: 3.402

Review 6.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

7.  In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites.

Authors:  Rubén E Varela-M; Janny A Villa-Pulgarin; Edward Yepes; Ingrid Müller; Manuel Modolell; Diana L Muñoz; Sara M Robledo; Carlos E Muskus; Julio López-Abán; Antonio Muro; Iván D Vélez; Faustino Mollinedo
Journal:  PLoS Negl Trop Dis       Date:  2012-04-10

8.  Oral treatment with T6-loaded yeast cell wall particles reduces the parasitemia in murine visceral leishmaniasis model.

Authors:  Débora B Scariot; Hélito Volpato; Nilma S Fernandes; Danielle Lazarin-Bidóia; Olga Borges; Maria do Céu Sousa; Fernanda A Rosa; Andrey P Jacomini; Sueli O Silva; Tânia Ueda-Nakamura; Adley F Rubira; Celso V Nakamura
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.